Navigation Links
Oncology basic research director at John Theurer Cancer Center continues transplantation research
Date:1/18/2011

HACKENSACK, N.J. (December XX, 2010) Thea Friedman, M.D., associate scientist and director of oncology basic research at the John Theurer Cancer Center at Hackensack University Medical Center was recently awarded a National Cancer Institutes of Health-National Cancer Institute (NIH-NCI) RO1 research grant to improve allogeneic blood and marrow transplantation for multiple myeloma patients. The grant provides $2 million in funding over the next five years.

As part of the John Theurer Cancer Center's continued efforts to improve outcomes of blood and marrow transplantation, Dr. Friedman and her colleagues have been using a molecular technique called T cell receptor Vβ CDR3 spectratype analysis to look at T-cell repertoires for the purpose of separating the donor cells responsible for graft-versus-host disease from those mediating graft-versus-tumor responses. Once separated, Dr. Friedman and her team will come closer to "personalized" transplantation, a huge milestone for the multiple myeloma community.

"This significant funding provided by the NIH is instrumental to further our blood and marrow transplant research," said Dr. Friedman. "We look forward to the possibility of using personalized transplantation to better the lives of cancer patients in our community and around the world."

The ROI research is the original and oldest grant mechanism used by NIH. The RO1 applications are peer reviewed and only those scoring above the 15th percentile are awarded. Last year, only 25 percent of the 50,000 applications were awarded a grant.

"The John Theurer Cancer Center constantly strives to provide the medical community with the latest advancements and innovations in oncology," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., chief innovations officer and professor and vice president of cancer services, the John Theurer Cancer Center. "Dr. Friedman and her colleagues' research is just one example of our commitment to advance innovative and treatment options in this fight against cancer."

Dr. Friedman first began this body of research in 2000 when she received a grant award from the National Marrow Donor Program. She applied for her first RO1 grant, which she was awarded in July 2003.

Dr. Friedman and her team plan to move their transplant research into a Phase I clinical trial in late 2011. Collaborators from the John Theurer Cancer Center include Robert Korngold, Ph.D., chief of oncology basic research; Scott Rowley, M.D., co-chief of blood and bone marrow stem cell & transplantation; David Siegel, M.D., Ph.D., chief of multiple myeloma and Michele Donato, M.D., collection facility medical director, blood & marrow transplantation.

In January 2011, the John Theurer Cancer Center's team of expert physicians, researchers and staff will begin transitioning into a new, $130-million comprehensive care facility. The new facility is equipped with a dedicated Phase 1 unit, tumor banking, new modalities of delivery of radiation and future molecular imaging technology to further support the development of innovative therapies and approaches to improve patient outcomes.


'/>"/>

Contact: Jaymie DeGaetano
jaymie.degaetano@widmeyer.com
646-213-7243
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. European Multidisciplinary Conference in Thoracic Oncology
2. Spanish Oncology to establish a new standard treatment on breast cancer at early stages
3. Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting
4. OncologyPRO: Unique portal for cancer specialists
5. Boston, Oct. 21-24: Largest international pediatric oncology conference
6. Grant will aid creation of interdisciplinary oncology palliative care education program
7. Elsevier and International Society of Geriatric Oncology launch Journal of Geriatric Oncology
8. Hematology-Oncology Associates of Northern New Jersey (HOANNJ) Joins Effort to Improve Cancer Care with Via Oncology™ Pathways
9. Space Coast Cancer Center Selects Via Oncology™ Pathways to Advance Evidence-Based Cancer Care
10. Peace of Mind Skin Care Announces new Services in Oncology Esthetics
11. Christiana Care Health Systems Darcy Burbage Receives Oncology Nursing Society Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Petersburg, Fla. (PRWEB) , ... February 20, 2017 , ... ... its research and education building. A topping out ceremony on Friday marked the halfway ... The building, set to open in Fall 2018, will serve as a center for ...
(Date:2/20/2017)... ... February 20, 2017 , ... Today, Illuma Care Connections, ... announced during the 2017 Annual HIMSS Conference & Exhibition in Orlando, ... patients and integrating eye care into mainstream healthcare delivery is powered by ...
(Date:2/19/2017)... ... 19, 2017 , ... The Citadel’s new Swain Department of Nursing , ... Amelia Joseph, Ph.D. Joseph was engaged by the college as a consultant to help ... 2016. After a nation-wide search, she was selected to head the department as nurse ...
(Date:2/19/2017)... ... ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made exclusively for ... with a glitch reveal in just a few clicks of a mouse. Customizable glitch style ... preset. Use these presets to add a uniquely animated logo to any photos or videos. ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... will join forces with Healthwise ® at HIMSS 2017 to ... leader in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... February 20, 2017 According to a new market ... Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), ... MarketsandMarkets, The market is projected to reach USD 52.37 Billion by 2021 ... the forecast period. Continue Reading ... ...
(Date:2/20/2017)... , February 20, 2017 Acute, Chronic and ... expected to grow at a CAGR of 7% from 2016-2021 and CAGR ... CAGR of 6% from 2016 to 2027. The market is estimated at ... ... Read on to discover how you can exploit the future business opportunities ...
(Date:2/19/2017)... Fla. , Feb. 18, 2017 Nektar ... positive Phase 1 clinical data for Nektar,s lead immuno-oncology ... were presented at ASCO GU 2017.  NKTR-214 is an ... cells and Natural Killer (NK) cell abundance directly in ... these immune cells.  The results were presented by ...
Breaking Medicine Technology: